Lyon (France), 17 may 2017 ERYTECH Pharma (Euronext Paris : ERYP), a biopharmaceutical company focused on clinical-stage developing from its proprietary platform of drug encapsulation in the red blood cells of innovative therapies against rare cancers and orphan diseases, will release its results for the 1st quarter of 2017 Thursday 18 may 2017 after market close, and will hold a webcast presentation on Friday, 19 may at 15: 00 (Paris time).
Download the free guide
Boost your gains
Gil Beyen, CEO of Erytech) Eric Soyer (Director of finance and operations Director) and Iman El-Hariry (medical Director) comment on the results of the 1st quarter of 2017 and the latest developments of ERYTECH during a conference call in English was broadcast live via a webcast followed by a question and answer session.
Investors and analysts wishing to participate in the webcast may access it through the following numbers :
France : +33 172001510 Germany : +49 69222229031
United States : +1 6467224907 Belgium : +32 24029640
United Kingdom : +44 2030432440 Switzerland : +41 225809022
The Netherlands : + 31 107138194 Sweden : +46 850334664
Finland : +358 942599700
Confirmation Code : 64683084#
Link to the live webcast :
http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135308821&PIN=64683084
Following the conference call, the replay will be possible for 90 days and available by calling the following numbers :
France : +33(0)1 72 00 15 00
United States: +1 877 64 230 18
United Kingdom : +44(0) 2033679460
Confirmation Code : 308821#
In addition, the webcast will be also accessible from the section “Webcast” of the “Investors” section of the site www.erytech.com
About ERYTECH : www.erytech.com
Created in Lyon in 2004, ERYTECH is a biopharmaceutical company in clinical stage that develops innovative therapies for the fight against rare cancers and orphan diseases. Building on its proprietary platform, ERYCAPS, which uses a new technology for the encapsulation of drugs into red blood cells, ERYTECH has developed a portfolio of product candidates targeting markets with high medical needs. The company is focused initially on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), depriving tumors of nutrients needed for their survival. ERYTECH is pursuing the approaches of the european regulation for the placing on the market of its product candidate flagship, eryaspase (also known as eryasp or its trade name : GRASPA®), after having shown the results of effectiveness and tolerance, positive in its clinical study pivotal european phase II/III children and adults in a relapse of a LAL, or with a LAL refractory. The company also leads in the United States a clinical study of phase I with eryaspase for adults with newly diagnosed of the LAL, and, in Europe, a phase II clinical study evaluating GRASPA® as first-line treatment for older patients with AML, each of the two treatments given in combination of chemotherapy. ERYTECH believes that eryaspase has the potential of a therapeutic approach for solid tumors. ERYTECH has conducted in France with success a Phase 1 clinical trial and a clinical study of Phase 2 with eryaspase in second-line treatment in patients with metastatic cancer of the pancreas.
Eryaspase (GRASPA®) consists of the encapsulation of an enzyme, L-asparaginase enzyme in red blood cells from donors. The L-asparaginase destroys in the blood plasma asparagine, an amino acid essential to the survival and proliferation of cancer cells. ERYTECH product eryaspase on its own production site which is already operational, and certified GMP (Lyon), and in a site of clinical production in Philadelphia, in the United States. ERYTECH has partnerships, licensing and distribution of GRASPA® in Europe for the LAL and LAM with Orphan Europe (Recordati group), and in Israel for the LAL with TEVA, both of which will start marketing the drug under the brand name GRASPA®.ERYTECH has obtained Orphan Drug designation by the regulatory agency (FDA) and the European Medicines Agency for its product eryaspase for the treatment of ALL, AML and pancreatic cancer.
In parallel eryaspase, ERYTECH is developing two other product candidates that consist of encapsulate enzymes to starve the tumors. ERYTECH also extends the use of its platform to develop immunotherapies in oncology (ERYMMUNE) and enzyme therapies in areas other than oncology (ERYZYME).
ERYTECH is listed on the regulated market of Euronext in Paris (ISIN Code : FR0011471135, mnémo : ERYP) and is part of indices CAC All Shares, CAC Healthcare, CAC Pharma & Bio, CAC Small, CAC Mid&Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech. The shares of ERYTECH are eligible in France to the device tax PEA-PME and are listed in the United States in the form of ADR of level 1 on the OTC market (Mnémo : EYRYY).
Download the free guide
Boost your gains
